This Friday, 21st March, is “World Down Syndrome Day”, an annual celebration introduced by the United Nations in 2012. The date 21/03 is highly symbolic, referring to the three copies of chromosome 21 related to Down syndrome. Its objective is to raise awareness and provide information about this genetic abnormality that affects one in every 700 live births, causing intellectual disability accompanied by other functional impairments — albeit not particularly serious — of the nervous, cardiac, digestive and immune systems.

In June 2011, the Madrid Down Syndrome Foundation proposed the wonderful initiative of organizing an outdoor exhibition entitled “Beyond a Face”, an event showcasing 132 large-format photographs, authentic works of art featuring children with Down syndrome, complemented by thought-provoking statements: “I have one extra chromosome. What’s different about you?”; “When I got home, Mum and Dad didn’t know what to do with me. Now they wouldn’t know what to do without me“; “If you want to, you can. If I want to, I can! When we want to, together we can“; “Only a select few have the ability to make others become better people. Only the best“; “It’s because of you that I see oceans, where there were only puddles“, etc.

If there is a particular quality that characterizes these individuals, it is their inherent joy from the moment they are born, winning the affection of their parents and siblings, as witnessed by the families that have or welcome them.

Efforts aimed at raising public awareness about safeguarding the lives and well-being of those with Down syndrome are inadequate. The focus should be on respecting them and helping their families successfully cope with the difficulties related to their health and education. The solution, however, is not to hide them, as was done in the past, or to prevent their birth through eugenic abortion following a prenatal genetic diagnosis, which is unfortunately becoming more prevalent today.

The French physician and geneticist Jérôme Lejeune (1926-1994), who discovered the cause of Down syndrome (trisomy of chromosome 21 [2n = 47 +21]) and who was a great advocate for children with this disorder, shared the idea that life is a gift from God and that every human being should be treated with the same dignity, regardless of their physical condition or health. He frequently remarked that the physician’s adversary is the disease, not the patient. Lejeune himself held on to the belief that his discovery would serve as a cornerstone to try to address the associated medical challenges.

In this regard, it is important to acknowledge the significant contributions made by the Jérôme Lejeune Foundation, promoted by the French geneticist himself and expanded by his wife Birthe Lejeune (1928-2020) following Lejeune’s death in 1995. The Foundation, based in Paris, dedicates between 4 and 5 million Euros per year to research, has a biobank in Paris with more than 20,000 samples, and another about to open in Madrid. It also has four medical centers, the first in Paris, which has served more than 13,000 patients, and three others in Nantes (France), Madrid, and Córdoba (Argentina).

Research to prevent the effects of the third chromosome 21

Aside from the clinical care and promotion of special education required by individuals with Down syndrome, it is essential to investigate its causes.

The complexity of the problem arises from the fact that it is not linked to a single or even a handful of genes, but rather to no less than 300 to 400 genes located on chromosome 21 of the nearly 21,000 protein-coding genes that make up the entire human genome. Our genome contains 23 pairs of chromosomes (2n = 46; 22”+XX or 22”+XY). Chromosome 21 has the lowest gene content in the genome because, although chromosome 22 is smaller, it has 800 genes. This explains why aneuploidy in which there is an extra chromosome, such as trisomy 21, is better tolerated, has fewer phenotypic effects, and results in fewer miscarriages than trisomies of any other chromosome, including trisomy 13 with 800 genes, which causes Patau syndrome, or trisomy 18 with 600 genes, responsible for Edward syndrome.

It is evident that behind the pathological symptoms caused by these trisomies — which are the only partially viable ones — there is an issue with overexpression of the triplicate genes they contain. To mitigate their effects, the expression of the genes in one of the three chromosomes would have to be silenced or blocked while ensuring that the activity of those contained in the other two with a normal gene complement remains unaffected.

A first approach to the problem would be to modulate the expression of those genes contained in the extra chromosome that are known to have a higher incidence in the altered phenotype. In this case, however, the issue lies in determining which genes are important and, once they are identified, applying some form of technology to silence them. The following sections will discuss several initiatives employed by different research groups to address this problem.

The DYRK1A gene and protein

According to research led by Dr. Mara Dierssen of the Center for Genomic Regulation (CRG) at the Barcelona Institute of Science and Technology, an excess of the DYRK1A protein, which produces the gene of the same name located on chromosome 21, causes a malformation of nerve endings similar to that found in individuals with Down Syndrome. Experiments carried out with transgenic mice in which the aforementioned gene has been inserted demonstrate the relationship between overexpression of the DYRK1A protein, neuron architecture and related brain function with the cognitive disorders observed in Down Syndrome [1]. However, this protein is not the only one responsible. In subsequent work by the same group in animal models, the authors underscored that this is undoubtedly an interesting line of research, which will allow us to discover more genes involved in Down syndrome. From then on, we will have to search for strategies to mitigate or silence their effects.

Gene expression domain dysfunction (GEDD)

Another strategy is to conduct comparative studies in monozygotic twins, one of which has Down syndrome (2n = 47 +21) while the other does not (2n = 46). A team led by Dr. Antonarakis from the Department of Medical Genetics and Development at the Faculty of Medicine, University of Geneva, discovered differences in expression in particular gene territories by comparing gene expressions between identical twins. This effect was termed “gene expression domain dysfunction” (GEDD). The researchers found 182 genes that varied in expression levels between identical twins, contrary to what is observed in dizygotic or non-identical twins. In other words, the trisomy causes a disturbance of gene regulation that can affect the rest of the genome. The authors concluded that the addition of a small piece of DNA of about 30 megabases (1% of a 3.1 billion base pair genome) can disturb the entire transcriptome. These findings demonstrate the complexity of the problem, which is related to disequilibrium in the intergenic interaction caused by trisomy of one of the copies of chromosome 21 [2].

Silencing the extra copy of chromosome 21 by inserting the Xist gene into the Dyrk1a locus

According to the above, an alternative approach to the problem would be the complete removal of the extra chromosome without altering the gene expression of the two remaining chromosomes.

A research group from the Department of Cell and Developmental Biology at the University of Massachusetts Medical School attempted to silence the extra chromosome 21 by applying a model to study the inactivation of human chromosomes based on the phenomenon of “lyonization”, whereby one of the two X chromosomes in mammalian females is naturally inactivated in the early cell divisions of embryonic development. Since the factor that causes this inactivation is the Xist gene, the researchers designed an in vitro transgenesis experiment to insert the aforementioned Xist gene into the Dyrk1a locus of chromosome 21 in induced pluripotent stem cells (iPSCs) from fibroblasts of a patient with Down syndrome. The result was that the non-coding RNA transcribed by Xist triggered DNA methylation and, as a result, compression of the entire chromosome 21 to form a “chromosome 21 Barr body”, leading to its transcriptional silencing. Following the application of Xist to iPSCs, several cell clones were rescued in which one to three copies of chromosome 21 were modified.

Consequently, it is possible to eliminate the expression of a minimum of one of the three copies of chromosome 21 involved in trisomy 21, at least in vitro, which is a major step towards achieving a future clinical application for the development of chromosome therapy [3]. There were still many challenges to overcome, such as reducing the silencing to only one of the three copies of chromosome 21 and translating gene silencing from an in vitro system to the cells of an adult patient.

How to remove one of the three copies of chromosome 21

A team of researchers from several Japanese institutions has attempted to develop an in vitro model to remove the supernumerary chromosome 21 using the CRISPR-Cas9 genome editing technique. To that end, they used iPSCs from skin fibroblasts of a patient with trisomy 21. The idea was to try to act on one particular chromosome out of the three, which given how gene editing technology works, meant targeting the “specific alleles” of that chromosome without affecting the other two. It involved making several cuts in its DNA, which were left unrepaired after the action of the Cas9 enzyme, to induce its loss without altering the other two copies of chromosome 21 [4].

CRISPR-Cas9 technology has emerged as a powerful tool for genome editing. It enables the precise editing, mutation or deletion of specific short DNA sequences at genomic locations with a known sequence.

Cas9 cuts both DNA strands at the same location (double-strand breaks or DSB). Under normal circumstances, these cuts tend to be repaired by eukaryotic molecular repair systems, and homologous end joining (HEJ) or non-homologous end joining (NHEJ) repair may occur. These mechanisms depend on genes that synthesize polymerase enzymes and DNA repair ligases, although they also affect other factors, such as the state of chromatin relaxation and the stage of the cell cycle.

Naturally, in the case of trying to eliminate an entire chromosome, the research group was not interested in repairing the breakpoints caused by the action of Cas9, so they used a method that interferes with the action of the genes involved in repair (antisense RNA) to suppress its activity. By suppressing the repair, after cleavage at multiple sites on the target chromosome, the elimination frequency of the targeted chromosome would increase.

Parental imprinting

One factor the authors took into account was the existence of “parental imprinting”, a phenomenon whereby chromosomes of maternal or paternal origin which, despite containing the same gene complement, incorporate different epigenetic marks at various points.

Of the three copies of chromosome 21 present in people with Down syndrome, two come from one parent due to a disjunction error during the first meiotic cell division that precedes gametogenesis. The other comes from the other parent. Most cases of trisomy 21 Down syndrome are due to non-disjunction during the first meiotic division of oogenesis, so it is the maternal oocyte that transmits two copies of chromosome 21 instead of one. Consequently, since the non-disjunction occurs following the recombination of homologous chromosomes in female meiosis, the three copies of chromosome 21 that arise after fertilization are genetically different (same gene content but with allelic variation), to which is added the different imprinting according to their paternal or maternal origin.

Therefore, if one of the three chromosomes is to be eliminated, the imprinting differences facilitate the development of specific CRISPR-Cas9 systems to target only one of the chromosomes. Thus, on the paternal chromosome 21, there is a small subset of imprinted genes whose expression is conditioned by the alleles of the maternal chromosome or chromosomes.

These genes include those that encode a cell adhesion molecule, superoxide dismutase type 1, mitochondrial ribosomal protein L39, and others, which are silenced by parental imprinting with respect to their counterparts from female gametogenesis. These genes or others could be useful for their recognition and for the specific deletion of the chromosome containing them following the implementation of the CRISPR-Cas9 system, without altering the other two.

The method to reduce chromosome 21 copies to two would be to identify multiple specific sequences in one of the three chromosomes and direct CRISPR-Cas9 activity against them. CRISPR-Cas9 technology using specific guide RNAs targeting around 50 regions distributed along the selected chromosome would induce its breakage via the Cas-9 enzyme. After its action, the target chromosome would be chopped up and unable to be repaired, leaving the structure and functional stability of the other two chromosomes intact; these would be the only ones that would pass to the daughter cells.

The experiment conducted in the laboratory

The authors carried out this work in vitro. To that end, they developed several iPSC lines from fibroblasts from a patient with trisomy 21. In their experimental design, they created trisomic iPSC lines with different combinations of imprinted genes and chose one of the chromosomes as a carrier of the Cas9 enzyme targets for deletion. The results obtained were promising, both as regards the elimination of the selected chromosome 21 and because no notable structural chromosomal aberrations were observed after applying cytogenetic banding and fluorescence techniques for karyotype analysis.

In addition, using statistical analysis to compare the original trisomy 21 cells with the rescued euploid cell clones, i.e., with the corrected chromosome complement, the latter were associated with a phenotypic improvement in elements such as the development of the human central nervous system and neurogenesis. This suggests that the loss of chromosome 21 is significantly associated with the genes expressed ​​in the nervous system during development.

Cell proliferation rates and mitochondrial function related to cell death were also evaluated, showing a slight increase in the proliferation rate, an improvement in mitochondrial function, and a significantly shorter doubling time in disomic cells obtained after the elimination of one chromosome 21, compared to trisomic cells.

The analysis was completed by applying the model directly on differentiated cells, fibroblasts, which is important to understand the clinical potential of this technique. Its validity in eliminating the target chromosome 21 in skin-derived primary fibroblasts was verified, albeit with lower effectiveness.

The authors concluded that the performance of this technology falls short of the expectations for a tool designed for clinical applications.

Future clinical potential of these research studies

Both the technique of silencing one chromosome 21 using Xist system gene therapy and chromosome editing using CRISPR/CAS9 to remove the extra chromosome 21 are initial steps that require a high degree of technical complexity. While they have yielded somewhat promising results, they are applicable only in preimplantation embryos, with all the risks inherent to genetic modification in embryos.

Despite facing enormous challenges, the hope of reversibly improving cellular fitness and the phenotypic characteristics of Down Syndrome remains.

Bioethical assessment

The application of gene editing in order to silence a few genes or a number of them in laboratory experiments, with undoubtedly encouraging results, opens prospects for future clinical interventions that could reduce or even eliminate the limiting phenotypic manifestations associated with trisomy 21.

Nevertheless, it should be stressed that genetically modifying cells in a laboratory setting is manifestly different from attempting to do so in vivo, i.e., on a zygote, so that these alterations could be transferred to all the individual’s cells.

The first difficulty lies in the fact that it would be impossible to perform the genetic diagnosis that would confirm trisomy in the single-cell embryo, the zygote. To do so would require waiting until this incipient embryo has at least 6-8 cells, which would make it difficult for the modifications introduced to affect all of them and subsequently extend to all the cell lines in the organism.

There is yet a further difficulty regarding the implementation of these developments, which has already been mentioned. Acting on certain protein-coding genes related to the phenotypic manifestation of the syndrome causes other unwanted (off-target) effects on several genes whose expression is related. The scope of these knock-on changes is currently unpredictable. Furthermore, the idea that these uncontrolled effects would eventually spread to the individual’s trillions of cells presents a scenario that is hard to imagine.

Nevertheless, efforts such as those outlined in this article, aimed at correcting the genetic anomalies responsible for trisomy 21 should be encouraged, in the hope that one day — as envisioned by its discoverer Jérôme Lejeune — the developmental and health challenges experienced by individuals with Down Syndrome will be overcome,

This is the bioethically plausible alternative and is diametrically opposed to today’s widespread eugenic practices, which condemn the vast majority of unborn people with Down syndrome to certain death as victims of abortion.

Even as these new clinical possibilities are being explored, much can still be done — now — to better the lives of those affected by the syndrome, whose humanity, gentleness and dignity remain undiminished, offering valuable lessons to us all.

Nicolás Jouve

Professor Emeritus of Genetics at the University of Alcalá

Member of the Bioethics Observatory of the Catholic University of Valencia

 

Julio Tudela

Director of the Institute of Life Sciences

Catholic University of Valencia

 

References

[1] Martínez de Lagran M, Benavides-Piccione R, Dierssen M. Dyrk et al. “DYRK1A influences neuronal morphogenesis through regulation of cytoskeletal dynamics in mammalian cortical neurons”. Cereb Cortex. 2012  (12):2867-2877.

[2]  Letourneau A. et al., Letourneau, A., Santoni, F. A., et al., “Domains of genome-wide gene expression dysregulation in Down’s syndrome”. Nature, 508 (2014) 345-350.

[3] Jiang, J., Jing, Y., Cost, G. et al. “Translating dosage compensation to trisomy 21”. Nature 500, (2013) 296–300.

[4]  Hashizume R, Wakita S, Sawada H, Takebayashi SI, Kitabatake Y, Miyagawa Y, Hirokawa YS, Imai H, Kurahashi H. “Trisomic rescue via allele-specific multiple chromosome cleavage using CRISPR-Cas9 in trisomy 21 cells.” PNAS Nexus. 2025 Feb 18;4(2):pgaf022.

Share This Story, Choose Your Platform!